Jasper Therapeutics (NASDAQ:JSPR) Stock Gets Downgrade from Wall Street Zen

Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday, Wall Street Zen reports.

A number of other research analysts have also weighed in on the company. Piper Sandler assumed coverage on Jasper Therapeutics in a research note on Wednesday, August 12th. They set an “overweight” rating and a $60.00 price target on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Friday, July 17th. William Blair began coverage on Jasper Therapeutics in a research note on Wednesday, October 14th. They issued an “outperform” rating for the company. Finally, HC Wainwright reiterated a “buy” rating on shares of Jasper Therapeutics in a research note on Tuesday, August 18th. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $220.00.

Read Our Latest Stock Report on Jasper Therapeutics

Jasper Therapeutics Stock Performance

Shares of JSPR opened at $13.68 on Friday. Jasper Therapeutics has a 1 year low of $9.45 and a 1 year high of $72.60. The company’s 50 day simple moving average is $16.79 and its 200 day simple moving average is $24.15. The company has a market capitalization of $15.18 million, a price-to-earnings ratio of -0.29 and a beta of 3.30.

Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) last released its earnings results on Friday, August 14th. The company reported ($3.00) EPS for the quarter, topping the consensus estimate of ($8.03) by $5.03. Equities analysts expect that Jasper Therapeutics will post -28.98 EPS for the current fiscal year.

About Jasper Therapeutics

(Get Free Report)

Jasper Therapeutics is a clinical-stage biotechnology company developing antibody-based therapies for conditions involving blood-forming stem cells and mast cells. Its research focuses on c-Kit, also known as CD117, a protein found on these cells. The company’s lead investigational drug, briquilimab (formerly JSP191), is a monoclonal antibody that targets c-Kit. Jasper has studied briquilimab as a conditioning treatment for stem cell transplantation and gene therapy, and is evaluating it for mast cell-mediated diseases, including chronic spontaneous urticaria.

Further Reading

Analyst Recommendations for Jasper Therapeutics (NASDAQ:JSPR)

Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.